Apply to trial NCT07079735

A few quick questions so the study team can decide if you might be a fit.

RecruitingDrug trial

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening